Literature DB >> 21080050

The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer.

Brian L Sprague1, Amy Trentham-Dietz, Patrick L Remington.   

Abstract

The striking decline in United States breast cancer incidence since 2002 has been widely attributed to a reduction in postmenopausal hormone use, yet very little analysis has been conducted to quantify the contribution of changes in hormone use to the declining trend. We used literature-based estimates of the relative risk and the changing prevalence of hormone use to estimate the impact of hormone use on the decline in breast cancer incidence between 2002 and 2003 among women aged 40-79. For the base case of a 44% decline in hormone use and a relative risk for current use of 1.5, we estimated that 43% of the decline in incidence was attributable to hormone use. By exploring a range of parameter values, we found that high, unlikely values of the relative risk (i.e., ≥ 2.25) and/or the percent decline in hormone use (i.e., ≥ 75%) would be required to account for 100% of the observed decline in breast cancer incidence. We conclude that hormone use is unlikely to account for more than half of the observed decline in breast cancer incidence between 2002 and 2003. Further efforts are needed to quantify the potential contributions of other factors, such as the plateau in screening mammography utilization.

Entities:  

Mesh:

Year:  2010        PMID: 21080050      PMCID: PMC3034386          DOI: 10.1007/s10552-010-9682-7

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  37 in total

1.  Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma.

Authors:  Janet R Daling; Kathleen E Malone; David R Doody; Lynda F Voigt; Leslie Bernstein; Ralph J Coates; Polly A Marchbanks; Sandra A Norman; Linda K Weiss; Giske Ursin; Jesse A Berlin; Ronald T Burkman; Dennis Deapen; Suzanne G Folger; Jill A McDonald; Michael S Simon; Brian L Strom; Phyllis A Wingo; Robert Spirtas
Journal:  Cancer       Date:  2002-12-15       Impact factor: 6.860

2.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.

Authors:  C Schairer; J Lubin; R Troisi; S Sturgeon; L Brinton; R Hoover
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

3.  Breast carcinoma in situ: risk factors and screening patterns.

Authors:  E B Claus; M Stowe; D Carter
Journal:  J Natl Cancer Inst       Date:  2001-12-05       Impact factor: 13.506

4.  Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women.

Authors:  C I Li; N S Weiss; J L Stanford; J R Daling
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

5.  Postmenopausal estrogen and progestin use in relation to breast cancer risk.

Authors:  Polly A Newcomb; Linda Titus-Ernstoff; Kathleen M Egan; Amy Trentham-Dietz; John A Baron; Barry E Storer; Walter C Willett; Meir J Stampfer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-07       Impact factor: 4.254

6.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

7.  Breast cancer and hormone-replacement therapy in the Million Women Study.

Authors:  Valerie Beral
Journal:  Lancet       Date:  2003-08-09       Impact factor: 79.321

8.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

9.  Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004.

Authors:  Christopher I Li; Janet R Daling
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-12       Impact factor: 4.254

10.  Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.

Authors:  Karla Kerlikowske; Diana L Miglioretti; Rachel Ballard-Barbash; Donald L Weaver; Diana S M Buist; William E Barlow; Gary Cutter; Berta M Geller; Bonnie Yankaskas; Stephen H Taplin; Patricia A Carney
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

View more
  4 in total

Review 1.  Effects of physical exercise on bone mineral density in older postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Keyvan Hejazi; Roya Askari; Martin Hofmeister
Journal:  Arch Osteoporos       Date:  2022-07-27       Impact factor: 2.879

2.  Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.

Authors:  R T Chlebowski; G L Anderson; G E Sarto; R Haque; C D Runowicz; A K Aragaki; C A Thomson; B V Howard; J Wactawski-Wende; C Chen; T E Rohan; M S Simon; S D Reed; J E Manson
Journal:  J Natl Cancer Inst       Date:  2015-12-14       Impact factor: 13.506

Review 3.  Targeted therapy for breast cancer prevention.

Authors:  Petra den Hollander; Michelle I Savage; Powel H Brown
Journal:  Front Oncol       Date:  2013-09-23       Impact factor: 6.244

4.  Muscular strength measurements indicate bone mineral density loss in postmenopausal women.

Authors:  Zhixiong Zhou; Lu Zheng; Dengyun Wei; Ming Ye; Xun Li
Journal:  Clin Interv Aging       Date:  2013-10-25       Impact factor: 4.458

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.